Article

Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.

2020-04-01

Abstract excerpt

<title>Abstract</title> <p>Background Cancer metastasis and drug resistance have traditionally been studied separately, though these two lethal pathological phenomena almost always occur concurrently. Brain metastasis occurs in a large proportion of lung cancer patients (~30%). Once diagnosed, patients have a poor prognosis surviving typically less than 1 year due to lack of treatment efficacy. Methods Human met...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: dd561042-675c-5969-8f3b-c6b1ce5e335e
DOI: 10.21203/rs.2.19597/v3

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Drug resistance occurred in a newly characterized preclinical model of lung cancer brain metastasis.DOI 10.21203/rs.2.19597/v3Read

Spotlight on the treatment of non-small cell lung cancer with rare genetic alterations and brain metastasis: Current status and future perspectives.Semantic proximity Read

Leptomeningeal metastases in non-small-cell lung cancer.Semantic proximity Read

Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?Semantic proximity Read

[Clinical Features of EGFR Mutation Negative in Patients with Non-small Cell Lung Cancer and Brain Metastases].Semantic proximity Read

Pharmacotherapeutic options for treating brain metastases in non-small cell lung cancer.Semantic proximity Read

First-line epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor alone or with whole-brain radiotherapy for brain metastases in patients with EGFR-mutated lung adenocarcinoma.Semantic proximity Read

Immune checkpoint inhibitors as first-line treatment for brain metastases in stage IV NSCLC patients without driver mutations.Semantic proximity Read

Navigating Uncharted Waters: Steering the Course and Confronting Challenges of Brain Metastases in EGFR-Mutant Lung CancerSemantic proximity Read

Management of brain metastasized non-small cell lung cancer (NSCLC) - From local treatment to new systemic therapies.Semantic proximity Read

High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with EGFR-mutant lung cancer cells.Semantic proximity Read

Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.Semantic proximity Read

Targeted Therapy in Brain Metastases: Ready for Primetime?Semantic proximity Read